Biocon gets USFDA nod for generic product
- Country:
- India
Biotechnology major Biocon on Thursday said its unit has received approval from the US health regulator to market a generic product.
Biocon Pharma, a subsidiary of the company, has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Mycophenolic Acid, the company said in a regulatory filing.
The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available in 180mg and 360mg strengths.
This approval further adds to Biocon's portfolio of vertically integrated complex drug products, the company noted.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- ANDA
- Biocon
- Mycophenolic Acid
- USFDA
- Food and Drug Administration
Advertisement
ALSO READ
With tears, a crowd of South Koreans bids farewell to beloved panda before her departure to China
South Koreans bid tearful farewell to beloved panda Fu Bao
Doval highlights need to shun double standards and hold sponsors, financiers and facilitators of terrorism accountable at NSA SCO meet
Polish PM Tusk says Gaza aid worker deaths cause 'understandable anger'
Uganda top court declines to block Anti-Homosexuality law but sees rights infringed
Google News